Alnylam Presents Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy at AAN 2021

 Alnylam Presents Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy at AAN 2021

Alnylam Presents Results of Vutrisiran in P-III HELIOS-A Study for Patients with hATTR Amyloidosis with Polyneuropathy at AAN 2021

Shots:

  • The P-III HELIOS-A study assessing Vutrisiran (25mg, SC, once every 3mos.) vs patisiran (0.3 mg/kg, IV, q3w) in 164 patients in a ratio (3:1) with hATTR amyloidosis with polyneuropathy
  • The study met its 1EPs & 2EPs i.e. change from baseline in mNIS+7 @9mos. & improvement in QoL assessed by Norfolk QoL-DN and gait speed assessed by timed 10-MWT. The therapy showed improvements in exploratory EPs @9mos., including NT-proBNP, overall disability and measures nutritional status
  • The company has submitted an NDA to FDA and plans to file the regulatory filing in Brazil and Japan and MAA in the EU upon obtaining the results of the 18mos. analysis from the P-III HELIOS-A study

Click here to­ read full press release/ article | Ref: Business Wire | Image: Stat News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post